International Urology and Nephrology最新文献

{"title":"Transgluteal MRI-targeted biopsy versus transrectal systemic biopsy in prostate cancer diagnosis.","authors":"Zixi An, Pengyu Sun, Min Liu, Jianwei Li, Chenyu Lin, Huaxing Zhu, Runsong Xue","doi":"10.1007/s11255-025-04522-1","DOIUrl":"10.1007/s11255-025-04522-1","url":null,"abstract":"<p><strong>Objective: </strong>To compare the detection rate of clinically significant prostate cancer (csPCa) between transgluteal in-bore magnetic resonance imaging-targeted biopsy (MRI-TB) and transrectal ultrasonography biopsy (TRUSBx) in biopsy-naïve men, and which technique has lower complication rates.</p><p><strong>Methods: </strong>From October 2021 to July 2024, clinical data were collected, retrospectively, from patients who underwent multiparameter MRI but had not previously undergone a prostate biopsy at hospital. The cases were considered based on the inclusion criteria. The patients were separated into two groups based on the prostate biopsy technique: TRUSBx (control group) and transgluteal MRI-TB (observation group). The csPCa detection and complications rates were compared between the two groups.</p><p><strong>Results: </strong>We gathered data from 150 patients. A total of 91 patients participated, comprising 58 in the control group and 33 in the observation group. The detection rates of csPCa in the two groups were 27.3% and 22.4%, respectively (P > 0.05). Subsequent analysis revealed no significant difference in the csPCa detection rate between the two groups concerning various TPSA levels, lesion location, prostate volume, maximal lesion diameter, and PI-RADS score (P > 0.05). There were notable discrepancies in the occurrence of overall complications and hemorrhage between the two groups (P < 0.05), although no significant variations were observed in the incidence of fever, hematochezia, and dysuria (P > 0.05).</p><p><strong>Conclusion: </strong>Transgluteal MRI-TB can diminish complications while preserving csPCa detection rates. The evidence indicates that transgluteal MRI-TB is a more secure alternative for patients at elevated risk of infection and hemorrhage. And the pathway does not necessitate puncture tray or associated anesthetic management facilities.</p>","PeriodicalId":14454,"journal":{"name":"International Urology and Nephrology","volume":" ","pages":"3499-3505"},"PeriodicalIF":1.9,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144011665","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Role of nicorandil in preventing contrast-induced nephropathy in patients undergoing cardiac catheterization procedures: an updated systematic review and meta-analysis.","authors":"Ahmed Ali Khan, Muhammad Zubair Tahir, Kanz Ul Eman Maryam, Muhammad Uzair, Haram, Muhammad Shaheer Bin Faheem, Zainab, Amna Abdullah, Ahmed Anwer, Danish Ali Ashraf, Amna Kaleem Ahmed, Sidrah Rahim, Muhammad Sameer Arshad","doi":"10.1007/s11255-025-04542-x","DOIUrl":"10.1007/s11255-025-04542-x","url":null,"abstract":"<p><strong>Background: </strong>Contrast-induced nephropathy (CIN) is a major risk for patients undergoing coronary angiography (CAG) and percutaneous coronary intervention (PCI).</p><p><strong>Methods: </strong>PubMed, MEDLINE, Embase, Google Scholar, and Web of Science were searched through May 2024 to include randomized controlled trials (RCTs) assessing the efficacy and safety of nicorandil administration in patients following CAG or PCI. Outcomes of interest included the CIN incidence, major adverse events, serum creatinine, serum cystatin C, BUN and eGFR. Risk ratios (RRs) and standard mean differences (SMDs) with 95% confidence intervals (CIs) were calculated using random-effects model. Statistical heterogeneity was assessed using I2 statistics.</p><p><strong>Results: </strong>Twelve studies (n = 2931 patients) were included in the final analysis. Nicorandil significantly reduced the CIN incidence (RR: 0.40 [0.31,0.52]; p < 0.00001), with consistent results for oral (RR: 0.35 [0.25,0.48]; p < 0.00001) and intravenous administration (RR: 0.52 [0.30,0.92]; p = 0.02) (p-interaction = 0.22). Oral nicorandil reduced the risk of major adverse events (RR: 0.71 [0.51,0.99]; p = 0.05). Among patients on nicorandil, serum creatinine levels were significantly lower at 48 h (SMD: -0.30 [-0.52,-0.07]; p = 0.009), and 72 h post-intervention (SMD: -0.42 [-0.71,-0.13]; p = 0.004). Nicorandil significantly reduced serum cystatin C levels at 48 h post-intervention (SMD: -0.56 [-1.01,-0.01]; p = 0.02). However, nicorandil did not significantly affect eGFR values at 24-h (SMD: 0.12 [-0.21,0.45]; p = 0.46), 48-h (SMD: 0.08 [-0.19,0.35]; p = 0.58), and 72-h (SMD: 0.34 [-0.13,0.81]; p = 0.16).</p><p><strong>Conclusion: </strong>Nicorandil administration reduces the CIN incidence and improves renal biomarkers in patients undergoing CAG and PCI. Large-scale trials with longer follow-up periods are warranted to confirm renoprotective effects of nicorandil.</p>","PeriodicalId":14454,"journal":{"name":"International Urology and Nephrology","volume":" ","pages":"3671-3685"},"PeriodicalIF":1.9,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144009722","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bladder and bowel dysfunction in children with sleep bruxism.","authors":"Aslı Öztürk, Hasan Cem Irkılata, Giray Ergin, Osman Evren Çelik, Onur Ağmaz, Hazal Özer, Murat Dayanç","doi":"10.1007/s11255-025-04491-5","DOIUrl":"10.1007/s11255-025-04491-5","url":null,"abstract":"<p><strong>Objectives: </strong>There is little evidence of a direct relationship between sleep bruxism and enuresis nocturna, and whether this enuresis is monosymptomatic or non-monosymptomatic nocturnal enuresis (MNE or NMNE) is unknown. The aim of the study is to investigate the type and frequency of nocturnal enuresis and other lower urinary tract symptoms (LUTS) in children with sleep bruxism.</p><p><strong>Methods: </strong>The children who applied consecutively to the Department of Pediatric Dentistry were included in this study. Sleep bruxism was determined by history and confirmed by clinical examination by pedodontist. LUTS were evaluated using the Dysfunctional Voiding and Incontinence Symptom Scale (DVISS). Patients with total DVISS score above 8.5 were accepted as having lower urinary tract dysfunction (LUTD). The relationship between bruxism and the presence of LUTD and LUTS was investigated. Patients with and without sleep bruxism were compared using the Mann-Whitney U test and Crosstab on SPSS 16.0.</p><p><strong>Results: </strong>A total of 184 consecutive children were included in the study. Sleep bruxism was present in 77 (41.8%) children and absent in 107 (58.2%) (control group). LUTD was detected in 19 (24.7%) children with bruxism and 11 (10.3%) without bruxism. The mean total score of DVISS, which was 5.43 in bruxers vs. 2.67 in non-bruxers, was significantly higher in the bruxism group (p = 0.012). NMNE, pain during voiding, intermittent urination, urination after voiding, urge incontinence, and constipation were significantly more common in children with bruxism (p values were 0.005, 0.025, 0.002, 0.0001, and 0.002, respectively).</p><p><strong>Conclusions: </strong>LUTD with enuresis nocturna and daytime symptoms (NMNE) is more common in children with sleep bruxism and LUTS can be easily questioned with a simple validated questionnaire.</p>","PeriodicalId":14454,"journal":{"name":"International Urology and Nephrology","volume":" ","pages":"3633-3638"},"PeriodicalIF":1.9,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144019562","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Metformin attenuates endoplasmic reticulum stress in diabetic kidney disease: mechanistic insights and future perspectives.","authors":"Bin Huang, Wenjie Wen","doi":"10.1007/s11255-025-04562-7","DOIUrl":"10.1007/s11255-025-04562-7","url":null,"abstract":"<p><p>Diabetic kidney disease (DKD) is a common microvascular complication of diabetes that can lead to end-stage renal failure. Emerging evidence suggests that endoplasmic reticulum (ER) stress plays a crucial role in the pathogenesis of DKD by affecting various renal parenchymal cells, including endothelial cells, podocytes, and mesangial cells. This review comprehensively examines the relationship between ER stress and DKD, focusing on how metformin, a first-line antidiabetic medication, ameliorates ER stress-induced kidney injury. Multiple factors, including reactive oxygen species (ROS), proteinuria, and advanced glycation end products (AGEs), contribute to ER stress in DKD. Metformin's renoprotective effects are primarily mediated through activation of the AMPK signaling pathway, which modulates ER stress response, reduction of oxidative stress and its impact on ER function, and improvement of mitochondrial function. These mechanisms collectively lead to decreased proteinuria, reduced cell apoptosis, and attenuated epithelial-mesenchymal transition in diabetic kidneys. Understanding these molecular mechanisms provides new insights into the therapeutic potential of metformin in DKD treatment. However, further research is needed to elucidate the precise molecular pathways through which metformin regulates ER stress in different renal cell types under diabetic conditions.</p>","PeriodicalId":14454,"journal":{"name":"International Urology and Nephrology","volume":" ","pages":"3701-3707"},"PeriodicalIF":1.9,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144002781","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Haemodialysis distress thermometer scale: Turkish validity and reliability study.","authors":"Serkan Budak","doi":"10.1007/s11255-025-04574-3","DOIUrl":"10.1007/s11255-025-04574-3","url":null,"abstract":"<p><strong>Purpose: </strong>This study aimed to translate and adapt the \"Haemodialysis Distress Thermometer Scale\" (HDDT) into Turkish and assess its validity and reliability.</p><p><strong>Methods: </strong>This study collected data from 223 haemodialysis patients across three public hospitals in Kütahya province, Türkiye, over a seven-week period.</p><p><strong>Results: </strong>In this study, the content validity index of the scale was determined to be 0.96. Validity analysis results indicated that factor loadings ranged between 0.45 and 0.82, the total variance explained was 59.25%, and the fit indices were X²/df = 1.149 and RMSEA = 0.026. Reliability analysis showed that the total Cronbach's α coefficient was 0.80, with item-total correlation coefficients ranging from 0.37 to 0.73. The cut-off score for the HDDT barometer was identified as 6.5. The final structure of the HDDT scale comprised 40 items, four factors, and an 11-point barometer, consistent with the original scale.</p><p><strong>Conclusion: </strong>The Turkish version of the HDDT is a valid and reliable instrument for assessing distress in patients undergoing haemodialysis treatment. It may serve as a valuable tool for nurses in identifying and addressing patient distress during haemodialysis care.</p>","PeriodicalId":14454,"journal":{"name":"International Urology and Nephrology","volume":" ","pages":"3839-3849"},"PeriodicalIF":1.9,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144110504","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comment on Yajima et al. (2025): \"Association between initial intravenous fluid volume and the composite outcome of hemodialysis dependence or in-hospital mortality in inpatients with rhabdomyolysis\".","authors":"Anfal Khan, Mohammad Idrees, Ameer Afzal Khan, Rahman Syed","doi":"10.1007/s11255-025-04589-w","DOIUrl":"10.1007/s11255-025-04589-w","url":null,"abstract":"","PeriodicalId":14454,"journal":{"name":"International Urology and Nephrology","volume":" ","pages":"3917-3918"},"PeriodicalIF":1.9,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144215802","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Short-term outcomes of triplet therapy in metastatic hormone-sensitive prostate cancer in older adults: a retrospective, single-center real-world cohort study.","authors":"Kimitsugu Usui, Hayato Kubo, Takahiro Matsumoto, Tomohiko Aigase, Atsuto Suzuki, Takeshi Kishida, Noboru Nakaigawa","doi":"10.1007/s11255-025-04465-7","DOIUrl":"10.1007/s11255-025-04465-7","url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate the efficacy and safety of triplet therapy in patients with metastatic hormone-sensitive prostate cancer (mHSPC), focusing on older adults, in a real-world clinical setting.</p><p><strong>Methods: </strong>In this retrospective, single-center study, we analyzed data from 21 patients with mHSPC (median age: 71 years) treated with androgen deprivation therapy (ADT), docetaxel, and darolutamide. Relative (≥ 90% reduction from baseline) and absolute (PSA < 0.2 ng/mL) prostate-specific antigen (PSA) response rates over 6 months were assessed, along with adverse event (AE) profiles.</p><p><strong>Results: </strong>At 6 months, the absolute PSA response rate was 71.4%, while the relative PSA response rate reached 100% by 3 months. Treatment-related toxicity was notable, with AEs observed in 95.2% of the patients, predominantly neutropenia. Patients aged ≥ 80 years had significantly higher treatment interruption rates for both docetaxel and darolutamide compared with those aged ≤ 79 years. Nonetheless, PSA response rates were comparable between the age groups. Neutrophil recovery time was significantly prolonged in patients aged ≥ 80 years compared to those aged ≤ 79 years.</p><p><strong>Conclusion: </strong>Triplet therapy effectively reduces PSA in patients with mHSPC, including older adults. However, the high incidence of severe AEs, particularly in older adults, underscores the need for individualized treatment strategies. Despite these challenges, careful management of toxicities makes this regimen viable in clinical practice. These findings emphasize the importance of real-world data in optimizing therapy for aging populations and may serve as a basis for future prospective studies comparing triplet and doublet therapies across diverse patient cohorts.</p>","PeriodicalId":14454,"journal":{"name":"International Urology and Nephrology","volume":" ","pages":"3543-3551"},"PeriodicalIF":1.9,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12504391/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144004749","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mechanisms and progress of LncRNAs in prostate cancer development and diagnostic therapy.","authors":"Shihan Zhao, Yuqi Liu, Han Wang, Jiayi Wang, Jihong Zhang, Yanbo Liu, Dongrui Ma","doi":"10.1007/s11255-025-04497-z","DOIUrl":"10.1007/s11255-025-04497-z","url":null,"abstract":"<p><p>Prostate cancer (PCa) is a leading cause of cancer-related morbidity and mortality in men worldwide. Despite advancements in diagnosis and treatment, challenges such as late-stage detection, therapeutic resistance, and the complexity of castration-resistant prostate cancer (CRPC) persist. Long non-coding RNAs (LncRNAs) play critical roles in PCa progression through epigenetic regulation, transcriptional and post-transcriptional modulation, and immune response regulation. This review highlights the molecular mechanisms by which LncRNAs influence PCa development, treatment resistance, and immune regulation, emphasizing their potential as biomarkers and therapeutic targets. We also discuss future research directions to advance precision medicine in PCa.</p>","PeriodicalId":14454,"journal":{"name":"International Urology and Nephrology","volume":" ","pages":"3481-3497"},"PeriodicalIF":1.9,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143995998","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Application effect of pelvic floor function exercise based on health belief model in patients with benign prostatic hyperplasia after electrocautery.","authors":"Juan Xiao, LiangJun Gui, HuaJuan Yao, ChengHong Liao, ShaoYan Yuan, Fang Xu, Jing Jing Zhong","doi":"10.1007/s11255-025-04454-w","DOIUrl":"10.1007/s11255-025-04454-w","url":null,"abstract":"<p><strong>Background: </strong>Benign prostatic hyperplasia (BPH) commonly affects men over 50, often requiring interventions like TURP. Postoperative pelvic floor muscle training (PFMT), guided by the Health BeliefModel (HBM), may enhance recovery, particularly in urinary and erectile function.</p><p><strong>Methods: </strong>Outcomes assessed included Health Promotion Lifestyle Profile II (HPLP-II) scores, International Prostate Symptom Scores (IPSS), International Index of Erectile Function-5 (IIEF-5), psychological states, and compliance behaviors.</p><p><strong>Results: </strong>In this retrospective case-control study, 180 men with BPH post-TURP were divided into a control group (standard care, n = 97) and an intervention group (PFMT based on HBM, n = 83). Post-intervention, the intervention group showed a significant improvement in HPLP-II, IPSS, and IIEF-5 scores compared to controls (P < 0.001). Prostate symptoms and erectile function improved markedly in the intervention group (IPSS: 5.16 vs. 8.39; IIEF-5: 20.08 vs. 20.99). Psychological assessments revealed lower anxiety and depression scores in the intervention group (SAS: 46.09 vs. 54.97; SDS: 42.15 vs. 53.29; P < 0.001). However, no significant differences in quality of life measures were reported between groups.</p><p><strong>Conclusion: </strong>PFMT guided by the HBM significantly improved urinary and erectile function, reduced postoperative complications, and enhanced psychological well-being in patients with BPH following TURP. These benefits should be evaluated in future longitudinal studies to assess their sustainability.</p>","PeriodicalId":14454,"journal":{"name":"International Urology and Nephrology","volume":" ","pages":"3507-3519"},"PeriodicalIF":1.9,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12504352/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143980862","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"DNMT1 promotes bladder cancer progression and immune escape by inhibiting MYH11 expression by methylating its promoter.","authors":"Shan Gao, Tianyi Liu, Qing Liu","doi":"10.1007/s11255-025-04527-w","DOIUrl":"10.1007/s11255-025-04527-w","url":null,"abstract":"<p><strong>Background: </strong>Bladder cancer (BC) is a fatal malignancy of the urinary tract with limited effective biomarkers and therapeutic targets. This paper delved into the mechanism of MYH11 and DNMT1 in BC progression.</p><p><strong>Methods: </strong>Differential genes obtained from the GSE3167 dataset were analyzed by the R language limma package. RT-qPCR, Western blot, and immunohistochemistry were carried out to assess MYH11 and DNMT1 expression in BC cell lines and BC tissues. Cell migration, invasion, proliferation, and apoptosis were detected by Transwell assay, CCK-8, and TUNEL after different lentiviral vector treatments. MB49 cells with different infections were administered into mice to monitor tumor growth and immune escape. Flow cytometry detected the rate of CD45⁺CD4⁺-positive cells in the tumor tissues and PD-1 and TIM-3 expression in CD4⁺ T cells. MYH11 methylation was analyzed using the qMSP assay. ChIP and dual-luciferase assay were used for regulatory assays.</p><p><strong>Results: </strong>MYH11 was lowly expressed in BC. Overexpression of MYH11 inhibited the malignant progression of BC cells, promoted anti-tumor immune responses of CD4⁺ T cells, and inhibited immune escape and tumor development in mice. DNMT1 inhibited MYH11 expression by elevating MYH11 promoter methylation. DNMT1 inhibition impeded the immune escape of BC cells, which was reversed by silencing MYH11. DNMT1 silencing prevented immune escape via transcriptional activation of MYH11 and hindered tumor growth in mice.</p><p><strong>Conclusion: </strong>DNMT1 promotes immune escape and malignant progression of BC by methylating the promoter of MYH11.</p>","PeriodicalId":14454,"journal":{"name":"International Urology and Nephrology","volume":" ","pages":"3595-3610"},"PeriodicalIF":1.9,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143987904","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}